The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women.
OBJECTIVE
To assess whether there are changes on anthropometric and biochemical measures of adiposity in pre- and postmenopausal women and in the latter before and after 6 months treatment with 17β-estradiol plus drospirenone.


METHODS
Twenty postmenopausal and 20 premenopausal women were enrolled in a prospective comparative study. Postmenopausal women received 1 mg 17β-estradiol plus 2 mg drospirenone daily for 6 months. Measurements of body mass index (BMI), waist/hip ratio and plasmatic levels of insulin, glucose, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, leptin, adiponectin, orexin-A, glucagon-like peptide-1 (GLP-1) and ghrelin were performed in premenopausal (group 1) and postmenopausal women and in the latter before (group 2a) and after (group 2b) 6 months treatment with 17β-estradiol plus drospirenone.


RESULTS
No significant changes in BMIs, insulin and glucose were observed between group 1 and 2a; and group 2a and 2b. GLP-1 levels were significantly increased in group 1 compared to group 2a (p = 0.035). Leptin levels were significantly increased (p = 0.001) and GLP-1 levels were significantly decreased (p = 0.021) in group 2b compared to group 2a. HDL was significantly decreased while LDL and triglyceride levels were significantly increased in group 2a compared to group 1. (p = 0.030, p = 0.001, p = 0.020; respectively) LDL was significantly decreased (p = 0.010) in group 2b compared to group 2a. GLP-1 had a positive correlation with orexin-A (p < 0.001, r = 0.520) and negative correlation with leptin (p = 0.008, r = -0.345).


CONCLUSIONS
Leptin was significantly higher and GLP-1 was significantly lower in women receiving 17β-estradiol plus drospirenone treatment. GLP-1 levels were significantly lower after the menopause compared to premenopausal levels. Orexin-A and GLP-1 were positively correlated.
Department of Obstetrics and Gynecology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Mesut
M
Karakus
Remise
R
Gelisgen
Ata
A
Topcuoglu
Onur
O
Guralp
Deniz
D
Topcuoglu
Gonul
G
Simsek
Seyfettin
S
Uludag
Hafize
H
Uzun
D052242:Adiponectin / Q000097:blood; D050154:Adiposity / Q000187:drug effects*; D000328:Adult; D000736:Androstenes / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D054439:Ghrelin / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D047908:Intracellular Signaling Peptides and Proteins / Q000097:blood; D020738:Leptin / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D009479:Neuropeptides / Q000097:blood; D000068797:Orexins; D017698:Postmenopause / Q000097:blood / Q000502:physiology*; D017697:Premenopause / Q000097:blood / Q000502:physiology*; D014280:Triglycerides / Q000097:blood; D049629:Waist-Hip Ratio
D052242:Adiponectin; D000736:Androstenes; D001786:Blood Glucose; D004967:Estrogens; D054439:Ghrelin; C000596229:HCRT protein, human; D007328:Insulin; D047908:Intracellular Signaling Peptides and Proteins; D020738:Leptin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D000451:Mineralocorticoid Receptor Antagonists; D009479:Neuropeptides; D000068797:Orexins; D014280:Triglycerides; D004958:Estradiol; D052216:Glucagon-Like Peptide 1; C035144:drospirenone